Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Br J Haematol. 2008 Mar 26;141(4):433–444. doi: 10.1111/j.1365-2141.2008.06982.x

Fig 5.

Fig 5

Superior clinical outcomes among patients receiving total therapy 2 (TT2) with gene expression profiling (GEP)-defined standard-risk versus high-risk myeloma. (A) Overall survival was highly superior in the low- versus high-risk group. (B) Event-free survival was highly superior in the low- versus high-risk group. (C) Duration of complete remission (CR) was highly superior in the low- versus high-risk group.